

## microRNA-based predictor for diagnosis of frontotemporal dementia

Running title: miRNA biomarkers for FTD

Iddo Magen<sup>1,2,†</sup>, Nancy-Sarah Yacovzada<sup>1,2,†</sup>, Jason D. Warren<sup>3</sup>, Carolin Heller<sup>3,4</sup>, Imogen Swift<sup>3,4</sup>, Yoana Bobeva<sup>5</sup>, Andrea Malaspina<sup>5,6</sup>, Jonathan D. Rohrer<sup>3</sup>, Pietro Fratta<sup>6</sup>, and Eran Hornstein<sup>1,2</sup>

1 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

2 Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

3 Dementia Research Centre, and 4 UK Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

5 Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

6 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

† Equal contribution

Correspondence to: Eran Hornstein, Arnold R. Meyer Building, Room 314, Weizmann Institute of Science, Rehovot 76100, Israel, email: [eran.hornstein@weizmann.ac.il](mailto:eran.hornstein@weizmann.ac.il).

Abstract word count: 150

Total word count (excluding title page, abstract, references and figure legend): 4870

No. of items (Figures, Tables, Supplementary): 5, 2, 6

References: 101

**Key words:** frontotemporal dementia; biomarker; microRNA; predictor; feature elimination.

## 1 **Abstract**

2 **BACKGROUND:** Frontotemporal dementia (FTD) is an early onset dementia that is diagnosed in  
3 ~20% of the progressive dementia cases. Heterogeneity in FTD clinical presentation too often  
4 delays clinical diagnosis and calls for molecular biomarkers to assist diagnosis, including cell free  
5 microRNAs (miRNA). However, nonlinearity in the relationship of miRNAs to clinical states and  
6 underpowered cohorts has limited research in this domain.

7 **METHODS:** We initially studied a training cohort of 219 subjects (135 FTD and 84 non-  
8 neurodegenerative controls) and then validated the results in a cohort of 74 subjects (33 FTD and  
9 41 controls).

10 **RESULTS:** Based on cell-free plasma miRNA profiling by next generation sequencing and  
11 machine learning approaches, we develop a nonlinear prediction model that accurately  
12 distinguishes FTD from non-neurodegenerative controls in ~90% of cases.

13 **DISCUSSION:** The fascinating potential of diagnostic miRNA biomarkers might enable early-  
14 stage detection and a cost-effective screening approach for clinical trials that can facilitate drug  
15 development.

## 16 Background

17 Frontotemporal dementia (FTD) is a neurodegenerative disease that is characterized by frontal  
18 and temporal lobe atrophy, and typically manifests with behavioral or language deficits <sup>1-4</sup>. The  
19 key known genetic drivers of FTD include hexanucleotide repeat expansion in the first intron of  
20 the gene chromosome 9 open reading frame 72 (*C9ORF72*) <sup>5,6</sup>, and mutations in the genes  
21 encoding for microtubule associated protein Tau (***MAPT***) <sup>7</sup>, Valosin-containing protein (*VCP*),  
22 TANK-binding kinase 1 (*TBK1*), progranulin (*GRN*), charged multivesicular body protein 2B  
23 (*CHMP2B*) and the RNA-binding protein TAR DNA-binding protein 43 (*TDP-43*) <sup>8-12</sup>. Relatedly,  
24 inclusions of Tau and TDP-43 are hallmarks of FTD neuropathology<sup>13, 14</sup>.

25 FTD can be difficult to diagnose, due to heterogeneity in clinical presentation <sup>1</sup>. Three main  
26 phenotypes of FTD are described: behavioral variant frontotemporal dementia (bvFTD),  
27 characterized by changes in social behavior and conduct, semantic dementia (SD), characterized  
28 by the loss of semantic knowledge, leading to impaired word comprehension and progressive  
29 non-fluent aphasia (PNFA), characterized by progressive difficulties in speech production <sup>1,15</sup>.  
30 Related motor variants within the FTD spectrum are corticobasal syndrome (CBS) and  
31 progressive supranuclear palsy (PSP) <sup>16</sup>. FTD further resides on a genetic and a clinico-  
32 pathological continuum with amyotrophic lateral sclerosis (ALS) <sup>17</sup>.

33 Brain imaging and several biofluid proteins have been proposed as biomarkers for FTD <sup>18-48</sup>.  
34 Among the proteins, noticeable are neurofilament light chain (NfL), TDP-43, and phospho-tau,  
35 amyloid beta and glial fibrillary acidic protein (GFAP). A recent study concluded that high NfL  
36 blood levels are indicative of the intensity of neurodegeneration or the extent of the degenerated  
37 axons in FTD <sup>26</sup>.

38 microRNAs (miRNAs) are a class of small, non-coding RNAs, that can be quantified in biofluids  
39 in a massively parallel fashion, yielding fine-grained profiles <sup>49</sup>. miRNAs were suggested as  
40 biomarkers in neurodegeneration and psychiatry <sup>50</sup>, and we too have shown their potential as cell-  
41 free biomarkers in neurodegeneration, focusing on the motor neuron diseases spinal muscular  
42 atrophy (SMA) and ALS <sup>51,52</sup>. Thus, low levels of miR-133 and miR-206 in the cerebrospinal fluid  
43 (CSF) of patients with SMA, predicted clinically meaningful response to nusinersen therapy <sup>51</sup>,  
44 whereas low plasma levels of miR-181 predict longer survival and slower progression in patients  
45 with ALS <sup>52</sup>.

46 Several studies suggested plasma or CSF miRNAs as diagnostic biomarkers for FTD<sup>53-62</sup>.  
47 However, initial studies of miRNAs in diagnosis of FTD were confounded by cohort size, sample

48 heterogeneity biases or pre-selection of candidate miRNAs. Furthermore, these studies did not  
49 address the potential non-linear relationships between miRNAs in developing a predictor.

50 In the current study, we profiled blood plasma miRNAs, and developed miRNA-based classifier  
51 for diagnosing FTD in a training cohort of 219 subjects, that was further validated in another cohort  
52 of 74 subjects. We implemented an ensemble machine learning approach, to address biomarker  
53 nonlinearity and were able to expose unrevealed disease-associated signals. We then confirmed  
54 that these signals are similar between clinical subtypes of FTD. The diagnostic power of the study  
55 roots from unbiased miRNA signature discovered by advanced machine learning, on a large and  
56 heterogeneous cohort, and validation in an independent held-out cohort, according to the TRIPOD  
57 guidelines<sup>63</sup>. Therefore, circulating miRNAs hold a fascinating potential as diagnostic biomarkers  
58 that may shorten diagnostic delay in FTD.

## 59 **Methods**

### 60 **Participants and Sampling**

61 Demographic data of study participants are detailed in Table 1.

62 FTD subjects and their respective controls were enrolled in the longitudinal FTD cohort studies at  
63 UCL. Study cohort included 169 FTD patients and 56 controls. Additional controls (N=102) were  
64 obtained from the ALS biomarker study (Ethics approval 09/H0703/27) in Queen Mary Hospital,  
65 totaling 158 non-neurodegenerative controls. Controls were typically spouses or relatives of  
66 patients and were not reported to have any clinical signs of ALS or FTD. Informed consent was  
67 obtained from all participants. Study inclusion period was from 2009 to 2018.

68 All FTD patients were seen at the National Hospital for Neurology and Neurosurgery, a national  
69 referral center for young and genetic dementias in the UK; the clinic has high diagnostic accuracy  
70 in cases that come to post mortem; for the majority of cases seen in the clinic CSF biomarkers of  
71 amyloid and Tau are used to distinguish FTD and AD whenever there is any question over  
72 accuracy of diagnosis.

73 Blood was collected by venipuncture in EDTA tubes, and plasma was recovered from the whole  
74 blood sample by centrifugation for 10 minutes at 3500 RPM at 4°C within 1 hour of sampling, and  
75 stored at -80°C until RNA extraction and subsequent small RNA next generation sequencing.  
76 Frozen plasma samples of FTD and controls from the UCL Biobanks were shipped to the  
77 Weizmann Institute of Science for molecular analysis.

### 78 **Study Design**

79 Based on power analysis calculations, we found that 150 controls and 150 cases are sufficient to  
80 obtain an ROC AUC of 0.7 with a power of 99% and a p-value of 0.0001. Phenotypic data on de-  
81 identified patients was separated and blinded during steps of the molecular analysis.

### 82 **Small RNA Next Generation Sequencing**

83 Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany)  
84 and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher  
85 Scientific, Waltham, MA). For small RNA next generation sequencing (RNA-seq), libraries were  
86 prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit and QIAseq miRNA NGS  
87 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples. Samples  
88 were randomly allocated to library preparation and sequencing in batches. Precise linear

89 quantification of miRNA is achieved by using unique molecular identifiers (UMIs), of random 12-  
90 nucleotide after 3' and 5' adapter ligation, within the reverse transcription primers<sup>49</sup>. cDNA  
91 libraries were amplified by PCR for 22 cycles, with a 3' primer that includes a 6-nucleotide unique  
92 index, followed by on-bead size selection and cleaning. Library concentration was determined  
93 with Qubit fluorometer (dsDNA high sensitivity assay kit; Thermo Fisher Scientific, Waltham, MA)  
94 and library size with TapeStation D1000 (Agilent). Libraries with different indices were multiplexed  
95 and sequenced on NextSeq 500/550 v2 flow cell or Novaseq SP100 (Illumina), with 75bp single  
96 read and 6bp index read. Fastq files were de-multiplexed using the user-friendly transcriptome  
97 analysis pipeline (UTAP)<sup>64</sup>. Human miRNAs, as defined by miRBase<sup>65</sup>, were mapped using the  
98 GeneGlobe pipeline (<https://geneglobe.qiagen.com/us/analyze>). We defined "true positive"  
99 miRNAs and reduced the likelihood of considering "false positive" miRNAs, following previous  
100 works on miRNA biomarkers in neurodegeneration<sup>58</sup> and other conditions<sup>66-68</sup>. To this end, we  
101 included only miRNAs with an average UMI counts > 100 across all samples and with at least a  
102 single UMI across all samples, similar to our previous works<sup>51,52</sup>. Data were further corrected for  
103 the library preparation batch in order to reduce its potential bias, and normalized with DESeq2  
104 package<sup>69</sup> under the assumption that miRNA counts followed negative binomial distribution

## 105 **Constructing Cohorts and Restricting Age and Sex Biases**

106 We observed a younger mean age in controls (53.8±14.5, 95% CI [51.5- 56.1]) than in FTD  
107 (65.6±8.4, 95% CI [64.4-67.0], Table S1). We reduced age-variance by excluding 34 participants  
108 younger than 40, which reduced differences in mean age across the remaining meta-cohort of  
109 293 subjects by 45%. Thus, 168 out of 169 FTD patients and 125 out of 158 non-  
110 neurodegenerative control samples were included in the analysis (Table S1). In order to verify  
111 that a merged dataset of controls, collected in two different clinical centers, does not introduce  
112 biases, we employed the t-distributed stochastic neighbor embedding (t-SNE) algorithm and  
113 measured Kullback–Leibler divergence, the difference between probability distributions. In  
114 addition, a higher prevalence of males was observed among FTD patients (65%) than among the  
115 controls (35%). Therefore, sex and age variables were added to the prediction model as  
116 covariates, in addition to the selected 13 miRNA predictors.

## 117 **Gradient Boosted Trees for the Development of Disease Binary Classifiers**

118 The FTD-disease binary classifier was developed using Gradient Boosting Classifier, a machine-  
119 learning algorithm that uses a gradient boosting framework. Diagnostic models were developed,  
120 validated and reported according to the TRIPOD guidelines<sup>63</sup> (<https://www.tripod->

121 [statement.org/](#)). Gradient Boosting trees <sup>70,71</sup>, a decision-tree-based ensemble model, differ  
122 fundamentally from conventional statistical techniques that aim to fit a single model using the  
123 entire dataset. Such ensemble approach improves performance by combining strengths of  
124 models that learn the data by recursive binary splits, such as trees, and of “boosting”, an adaptive  
125 method for combining several simple (base) models. At each iteration of the gradient boosting  
126 algorithm, a subsample of the training data is selected at random (without replacement) from the  
127 entire training data set, and then a simple base learner is fitted on each subsample. The final  
128 boosted trees model is an additive tree model, constructed by sequentially fitting such base  
129 learners on different subsamples. This procedure incorporates randomization, which is known to  
130 substantially improve the predictor accuracy and also increase robustness. Additionally, boosted  
131 trees can fit complex nonlinear relationships, and automatically handle interaction effects between  
132 predictors as addition to other advantages of tree-based methods, such as handling features of  
133 different types and accommodating missing data. Hence, in many cases their predictive  
134 performance is superior to most traditional modelling methods. Additional gain of these algorithms  
135 is the various loss functions that can be applied. Using the softmax loss function, we explicitly  
136 estimated the class conditional probabilities, which allow us to demonstrate the performance of  
137 each of the classifiers both as “soft-classifiers” (i.e., predicting class probabilities) and “hard-  
138 classifiers” (i.e., setting a probability threshold and predicting a class). The former approximates  
139 a continuous number as output - the class conditional probabilities - and then performs  
140 classification based on these estimated probabilities. In contrast, hard classifiers output a discrete  
141 number as the decision - directly targeting the classification decision boundary, without producing  
142 the probability estimation.

143 A gradient boosting classifier was developed with a feature set of 132 miRNA predictors.  
144 Dataset was partitioned to training-set (75%) and validation-set (25%) which was used as held-  
145 out data. The training-set was cross-validated during training with stratified 3-fold cross  
146 validation. An ROC was generated for each of the folds and individual and mean AUCs were  
147 calculated along with 95% confidence intervals.

148 The chosen hyper-parameters: `ccp_alpha=0.0`, `learning_rate=0.5`, `max_depth=8`,  
149 `max_features=0.45`, `min_samples_leaf=14`, `min_samples_split=8`, `n_estimators=100`,  
150 `subsample=0.45` and `tol=0.0001`.

## 151 **miRNA Predictor Selection by Recursive Feature Elimination (RFE)**

152 For selecting the most predictive features during prediction model development, we used  
153 *Recursive Feature Elimination* (RFE) algorithm, an efficient recursive approach for eliminating  
154 features from a training dataset with 3-fold cross validation. ExtraTreesClassifier algorithm is used  
155 in the cross-validated RFE procedure, with hyper-parameters: criterion="entropy",  
156 max\_features=0.9, and n\_estimators=20. RFE works by iteratively removing features and using  
157 model accuracy to identify which features contribute the most to prediction. Tree-based  
158 importance scores of 132 miRNAs were used in order to rank features, and thus reduced the  
159 dimension of miRNA measurements needed for prediction by ~90% (13 miRNA features in a  
160 model in total). Additionally, the final model included age and sex as predictors (resulting in a of  
161 total 15 predictors).

## 162 **Feature Importance and SHAP Analysis**

163 Although gradient boosting tree models are complex models, they can automatically provide an  
164 approximation of feature importance from the trained boosted trees. A miRNA predictor is  
165 assigned with an importance score in every single tree, where the Gini purity index is used to  
166 assess split points in the tree. The score of a feature is calculated based on the amount of  
167 improvement in the Gini index achieved by split points that include the feature, weighted by the  
168 number of observations in that node. The final importance score of a feature is calculated by an  
169 average across all decision trees within the final model.

170  
171 For local interpretability of the predictive model, we used SHapley Additive exPlanations (SHAP)  
172 <sup>72</sup>, the current state of the art in Machine Learning explainability tools. SHAP provides estimates  
173 and visualizations to infer what decisions the model is making. This is achieved by quantifying the  
174 contribution that each feature brings to each prediction made by the model.

## 175 **Linear regression model**

176 A linear classifier (Logistic Regression) was developed with a feature set of 95 miRNA predictors,  
177 that were differentially expressed (adjusted p-value  $\leq 0.05$ ) between FTD cases and controls.  
178 Each miRNA was binarized by its mean value. Training and validation were identical as in the  
179 gradient boosting classifier: Dataset was partitioned to training-set (75%) and validation-set (25%)  
180 which was used as held-out data. The training-set was cross-validated during training with  
181 stratified 3-fold cross validation. An ROC was generated for each of the folds and individual and  
182 mean AUCs were calculated along with 95% confidence intervals. The chosen hyperparams for  
183 Logistic Regression: L2 penalty, tol=1e-4, fit\_intercept=True, solver='lbfgs', max\_iter=500.



## 184 **Results**

185 We sought to determine the overall diagnostic capability of miRNA measurements in FTD. To this  
186 end, we based our study on analysis of plasma miRNA expression and the development of  
187 computational diagnostic models. The cohort included a total of 293 participants, enrolled  
188 between 2009 and 2018. Summary of participants' basic characteristics is shown in Table 1. Since  
189 the non-neurodegenerative controls were collected in two centers, we first verified that they could  
190 have been sampled from a single population and can therefore be considered a single cohort. We  
191 estimated the Kullback–Leibler divergence, a measure of the difference between two probability  
192 distributions. This analysis indicated only a small difference between the two sets in question (KL  
193 = 0.293, Figure S1), that is further visualized by t-distributed stochastic neighbor embedding (t-  
194 SNE) analysis of the cohorts.

### 195 **Differential expression of miRNAs**

196 Out of the >2000 miRNA species that were aligned to the human genome, only 132 fulfilled QC  
197 criteria of an average UMI count  $\geq 100$  across all samples and non-zero counts in all samples  
198 (see Methods). Next, we quantified the differential miRNAs that may distinguish FTD from  
199 controls. Ninety-five miRNAs were differentially expressed between plasma of patients with FTD  
200 and controls, with an adjusted p-value < 0.05 (Figure 1A). Additional analysis of only subsets of  
201 C9ORF72-FTD cases (Figure 1B), FTD females (Figure 1C) or FTD males (Figure 1D) vs.  
202 relevant controls revealed that the miRNA signature was comparable between the full FTD cohort  
203 and subcategories (Table S2: Source Data Fig. 1). This was also true for subsets of FTD patients  
204 with predicted TDP or Tau pathology (Figure S2).

### 205 **Development of machine learning classifier for the diagnosis of FTD**

206 We established a diagnostic prediction model for FTD on a randomly selected training set of 135  
207 FTD cases and 84 controls, comprising 75% of the total cohort (168 cases, 125 controls). For  
208 model validation, the remaining 25% of the data were held out as a replication cohort (33 FTD,  
209 41 control samples).

210 The 132 miRNAs were tested as potential predictors, using an ensemble machine learning  
211 approach for ranking miRNAs predictive value in the diagnosis of FTD vs. individuals that did not  
212 suffer from neurodegeneration and were considered healthy. For selecting the most predictive  
213 features during model development, we used Recursive Feature Elimination (RFE), an efficient  
214 multivariate approach that iteratively removes miRNAs (features) and identifies those that

215 contribute the most to prediction accuracy. Cross validated RFE on the training set with Extra  
216 Tree classifiers, obtained a set of 13 miRNAs with highest feature importance (Figure 2A). Age  
217 and sex were added as predictors in the model, in addition to the selected 13 miRNAs features.

218 The prediction model presented a mean receiver operating characteristic area under the curve  
219 (ROC AUC) of 0.94 under internal cross validation on training dataset (Figure 2B). Furthermore,  
220 the 13-miRNA-based predictor was capable of predicting the diagnosis of FTD in an independent  
221 held-out (replication) cohort of 74 individuals with an ROC AUC of 0.88 (Figure 2C). Additional  
222 analysis reveals that the model is well calibrated and satisfactorily performs on held-out data  
223 (Figure 2D). At a defined probability threshold (0.6), the classifier exhibits a 0.81 precision (PPV)  
224 over 0.92 negative predictive value (NPV) with a 0.91 recall (sensitivity), a 0.83 specificity and a  
225 0.08 false omission rate over 0.19 false discovery rate values (Figure 2E). Furthermore, a family  
226 of models trained with only a subset of the 15 most predictive features, displays a stable AUC  
227 ROC performance and reassures that the selected final features are suitable (Figure 2F). In  
228 summary, we determined 13 miRNAs that are able to call the diagnosis of FTD with high accuracy.  
229 We have further compared the non-linear machine-learning strategy (with 13 miRNA features  
230 selected by multivariate RFE, Figure 2) to a logistic regression model with univariate feature  
231 selection (Figure S3). A subset of 95 miRNAs out of the 132 passing QC, were differentially  
232 expressed between FTD and controls (passing a threshold of  $p < 0.05$  after correction for multiple  
233 hypotheses) and therefore were used in the logistic regression as features. Similarly, age and  
234 sex were also included as predictors. The linear model with 95 differentially-expressed miRNAs,  
235 age and sex was inferior to the gradient boosting classifier model, particularly by sensitivity (0.73  
236 vs 0.91) and negative predictive value (0.8 vs 0.92) (Figure S3). Moreover, the non-linear  
237 approach showed better robustness in the different training folds and also outperforms the linear  
238 model in utilizing a significantly smaller number of miRNA features (15 vs. 97), to obtain its  
239 accuracy.

240 We then sought to better understand the machine-learning-based non-linear prediction model by  
241 investigating the relative effect of each individual miRNA. Therefore, we utilized post-hoc SHapley  
242 Additive exPlanations (SHAP) feature importance analysis to uncover the contribution of  
243 individual miRNAs to the FTD diagnostic predictor (Figure 3A, B). Extreme SHAP values inform  
244 that the model predicts a more likely FTD (positive values) or healthy control (negative values).  
245 The key predictors revealed by SHAP, which contribute the most to calling FTD vs controls, are  
246 multiple sclerosis-associated miR-629<sup>73,74</sup>, brain enriched miR-125b<sup>75</sup> and the astrocyte-derived  
247 exosomal miR-361<sup>76</sup>. We further tested each individual miRNA as a single predictor of FTD

248 diagnosis. A model with only miR-423-5p or miR-125b-5p presented the highest AUC values of  
249 ~0.69 (Table 2). Boxplots depicting the underlying distribution of each of the 13 miRNA predictors,  
250 along with scatter plots of the expression values of individual subjects in these miRNAs, confirm  
251 the non-linear relationship between miRNA expression and the phenotype, for some miRNAs  
252 (e.g., miR-107 and miR-26a), while other miRNAs can be divided to low/high values predominated  
253 by either controls or FTD cases (e.g., miR-629-5p, Figure 4). These observations emphasize the  
254 power of a model, which is able to take into account non-linear relationship between features  
255 (miRNAs).

256 Significant pairwise differences were noted in miR-107 levels in both bvFTD and SD vs other FTD  
257 subtypes (primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy  
258 and FTD with motor neuron disease. ANOVA:  $p=0.009$ , bvFTD vs other FTD subtypes:  $p=0.01$ ,  
259 SD vs other FTD subtypes:  $p=0.02$ , Figure S4C). In addition, significant pairwise differences in  
260 miR-26a levels were found in both bvFTD ( $p=0.04$ ) and PNFA ( $p=0.02$ ) vs other FTD subtypes  
261 (ANOVA:  $p=0.024$ , bvFTD vs other FTD subtypes:  $p=0.04$ , PNFA vs other FTD subtypes:  $p=0.02$ ,  
262 Figure S4F).

263 None of the other miRNAs showed differences between clinical subtypes (Figure S4), between  
264 different mutation carriers, or between mutations carriers and patients with no known FTD  
265 mutations (Figure S5). In conclusion, a non-linear signature based on only 13 miRNAs is able to  
266 call the diagnosis of FTD with high accuracy and generalizability, for all FTD subtypes and  
267 independent of the underlying genetic background.

268 Finally, we tested the performance of plasma miRNA classifiers that were reported in previous  
269 works <sup>56,58</sup>, relative to the classifier we have reported here. We replicated the logistic regression  
270 model (with L2 regularization<sup>77,78</sup>) from the study of Kmetzsch et al. <sup>58</sup> on our data. Taking miR-  
271 34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p as features, displayed inferiority to our model.  
272 Moreover, these miRNAs were not differentially expressed between cases and controls in our  
273 study. Next, we replicated the "microRNA pair" approach from the study of Sheinerman et al. <sup>56</sup>:  
274 miR-335/let-7e, miR-99b/let-7e and miR-9-3p/miR-181a and assessed the ROC curves, showing  
275 they are inferior to our non-linear classifier in distinguishing between FTD and controls (Figure 5).  
276 Thus, when tested in comparison to reported miRNA classifiers from the literature, our panels of  
277 miRNA and non-linear classifier perform better, with AUC values of 0.9.

## 278 Discussion

279 The need to facilitate the diagnosis of FTD in the face of clinical heterogeneity raises the hope for  
280 new effective biomarkers. Circulating miRNAs hold a fascinating potential as diagnostic  
281 biomarkers that were not fully explored, including for brain disorders<sup>50</sup>. We recently demonstrated  
282 the power of miRNAs in prognosis and prediction of clinical response to therapy in motor neuron  
283 diseases<sup>51,52</sup>. In the present work, we sought to discover diagnostic biomarkers for FTD. By using  
284 an unbiased, next generation sequencing approach and advanced computation in a discovery  
285 cohort of 219 subjects and 74 additional subjects for a replication study, we overcame limitations  
286 of past works in developing biomarkers for FTD. A recursive non-linear approach was utilized to  
287 find the smallest set of miRNA features that obtain the highest accuracy of the prediction model,  
288 leading to a signature of 13 miRNAs only. Thus, our miRNA-based binary classifier is more  
289 accurate and robust than published miRNA-based predictors<sup>56,58</sup>.

290 The use of gradient boosting trees, an ensemble learning approach, allows discovering nonlinear  
291 relationships between miRNAs and disease status that gained affirmation by cross validation in  
292 the training dataset. Furthermore, our model is externally validated on held-out data, which was  
293 not used during feature selection and model development, according to the TRIPOD guidelines  
294<sup>63</sup>. SHAP analysis<sup>72</sup> further unfolds the relative contribution of individual features to the predictive  
295 model. Of note, the performance of the ensemble learning was superior to that of a logistic  
296 regression model, and enabled the use of only 15 features, instead of 97, for prediction.

297 According to the human miRNA tissue atlas<sup>75</sup>, most of the selected miRNAs are CNS-enriched  
298 (let-7c-5p, miR-26a-5p, miR-107, miR-125b-5p), suggesting that they might be directly involved  
299 in the disease state of the CNS. miR-26a, miR-326, miR-484 and miR-361 were associated with  
300 FTD diagnosis in our data and with cognitive deficits or Alzheimer's disease (AD) in other analyses  
301<sup>79-85</sup>. In mice, miR-326 inhibited Tau phosphorylation<sup>80</sup>, a hallmark of FTD as well as AD,  
302 supranuclear palsy (PSP), corticobasal syndrome (CBD) and chronic traumatic encephalopathy  
303 (CTE)<sup>86</sup>. Brain-enriched miR-107 was also implicated in AD<sup>87-92</sup>. Changes in blood levels of miR-  
304 326, miR-26a, and miR-629 are associated with multiple sclerosis (MS), a condition characterized  
305 by demyelination<sup>93-100</sup>. Moreover, serum miR-629 was negatively correlated with MS patient brain  
306 volume and lesion severity, respectively<sup>101</sup>. Thus, some of the miRNA predictors proposed here  
307 are associated directly or indirectly with other degenerative brain diseases.

## 308 **Conclusion**

### 309 **Strengths and Limitations**

310 We have found specific molecular miRNA patterns that can contribute to the diagnosis of FTD.  
311 Therefore, the work encourages testing if circulating miRNAs biomarkers can establish a cost-  
312 effective screening approach to increase speed or precision in the diagnosis of suspected FTD.  
313 Early-stage diagnosis may be useful towards design of prospective clinical trials. More broadly,  
314 the findings demonstrate the importance of integrating machine learning into clinical biomarker  
315 studies, addressing nonlinearity and exposing otherwise cryptic disease-associated signals.  
316 Finally, while ongoing biomarker studies in FTD highlight protein markers such as NfL and Tau,  
317 combined protein-RNA markers may present increased accuracy, as we previously showed<sup>52</sup>.  
318 We would like to put forward a few notable limitations of our study: First, patients in our cohorts  
319 were most likely recruited in different phases of the disease, which results in significant phenotypic  
320 heterogeneity. At the same time, since we had no record of disease severity, we could not stratify  
321 patients by their disease phase and depict stage-dependent changes in miRNAs. Additionally, we  
322 did not find any miRNAs, which can differentiate between FTD-Tau and FTD-TDP, which might  
323 result from small, underpowered subset cohorts or could highlight a wider role for these novel  
324 biomarkers within dementia syndromes. We hope that in the future, larger cohorts can be used to  
325 reveal such differences. Finally, a long route is expected from this initial study and until miRNA  
326 can be used in personalized diagnosis. These steps shall include prospective studies, quantitative  
327 calibration of absolute miRNA concentrations and simple bed-side methods for quantification of  
328 miRNAs.

### 329 **Unanswered questions**

330 It remains to be determined why our findings are discrepant with conclusions of past studies<sup>53-</sup>  
331<sup>60,62</sup>. For studies in other bodily fluids the answer might be trivially-related to the different biofluid  
332 composition<sup>53,57,60</sup>. Furthermore, we emphasize the progress we presented in our study in terms  
333 of power (larger cohort) and the unbiased analysis by next generation microRNA sequencing, that  
334 contrasts past biased choices of miRNA candidates. A second unanswered question is why  
335 defined nonlinear patterns are strongly predictive of disease states. Future works should address  
336 the differential diagnosis between FTD and other dementias, such as Alzheimer's disease. Lastly,  
337 protein based markers, such as neurofilaments, lack specificity to particular neurodegenerative  
338 diseases. However, it is plausible that miRNAs might demonstrate a disease-specific pattern in  
339 the circulation. Future studies with large AD and FTD cohorts might address this hypothesis.

## 340 **Recommendations**

341 In our study we took care to keep a held-out cohort for external validation. To substantiate our  
342 work and towards clinical diagnostic usage, it is warranted to validate the predictor by testing it  
343 on an independent cohort of different ethnicity and create means for quantification of absolute  
344 miRNA concentrations. In addition, miRNA levels should be compared in follow up works, and  
345 combined with other experimental circulating markers of neurodegeneration such as  
346 neurofilaments. In addition, miRNAs could be explored also as prognostic markers in FTD and in  
347 predicting disease severity.

## 348 **Availability of supporting data**

349 The data that support the findings of this study are available from the corresponding author upon  
350 reasonable request.

## 351 **Appendix**

### 352 **IDs of 34 subjects removed due to age-based QC:**

353 'CTRL\_rep9', 'CTRL\_rep10', 'CTRL\_rep13', 'CTRL\_rep19', 'CTRL\_rep16', 'CTRL\_rep18',  
354 'CTRL\_rep20', 'FTD30', 'CTRL\_rep17', 'CTRL12', 'CTRL13', 'CTRL2', 'CTRL5', 'CTRL56',  
355 'CTRL57', 'CTRL58', 'CTRL68', 'CTRL100', 'CTRL111', 'CTRL20', 'CTRL22', 'CTRL23', 'CTRL24',  
356 'CTRL27', 'CTRL29', 'CTRL33', 'CTRL48', 'CTRL50', 'CTRL54', 'CTRL60', 'CTRL62', 'CTRL73',  
357 'CTRL82', 'CTRL83'.

## 358 **Acknowledgements**

359 We thank Vittoria Lombardi (UCL) for technical assistance. We acknowledge patients with FTD,  
360 and healthy volunteers for their contribution and ALS biomarkers study co-workers for biobanking,  
361 which has made this study possible (REC 09/H0703/27). We also thank the North Thames Local  
362 Research Network (LCRN) for its support. EH is the Mondry Family Professorial Chair and Head  
363 of the Nella and Leon Benozio Center for Neurological Diseases and of the Andi and Larry Wolfe  
364 Center for Neuroimmunology and Neuromodulation.

## 365 **Funding**

366 Research at the Hornstein laboratory is supported by the CReATe consortium and ALSA  
367 (program: "Prognostic Value of miRNAs in Biofluids From ALS Patients"), the RADALA  
368 Foundation; AFM Telethon (20576); the Weizmann Center for Research on Neurodegeneration



369 at Weizmann Institute of Science; the Minerva Foundation, with funding from the Federal German  
370 Ministry for Education and Research; the ISF Legacy Heritage Fund (828/17); the Israel Science  
371 Foundation (135/16, 3497/21, 424/22, 425/22); United States - Israel Binational Science  
372 Foundation (#2021181); A research grant from the Anita James Rosen Foundation; Target ALS  
373 (118945); the Thierry Latran Foundation for ALS Research; the European Research Council  
374 under the European Union's Seventh Framework Program ([FP7/2007–2013]/ERC grant  
375 agreement number 617351); ERA-Net for Research Programs on Rare Diseases (eRARE FP7)  
376 via the Israel Ministry of Health; Dr Sydney Brenner and friends; Edward and Janie Moravitz; A.  
377 Alfred Taubman through IsrALS; Yeda-Sela; Yeda-CEO; the Israel Ministry of Trade and Industry;  
378 the Y. Leon Benozio Institute for Molecular Medicine; the Nella and Leon Benozio Center for  
379 Neurological Disease; the Kekst Family Institute for Medical Genetics; the David and Fela Shapell  
380 Family Center for Genetic Disorders Research; the Crown Human Genome Center; the Nathan,  
381 Shirley, Philip, and Charlene Vener New Scientist Fund; the Julius and Ray Charlestein  
382 Foundation; the Fraida Foundation; the Wolfson Family Charitable Trust; the Adelis Foundation;  
383 Merck (UK); M. Halphen; the estates of F. Sherr, L. Asseof, and L. Fulop; the Goldhirsh-Yellin  
384 Foundation; the Redhill Foundation–Sam and Jean Rothberg Charitable Trust; Dr. Dvora and  
385 Haim Teitelbaum Endowment Fund; A research grant from the Anita James Rosen Foundation.  
386 The ALS-Therapy Alliance, Motor Neuron Disease Association (UK); this work was supported by  
387 the Motor Neuron Disease Association (MNDA) 839-791.  
388 The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research Trust,  
389 and The Wolfson Foundation. This work was supported by the NIHR Queen Square Dementia  
390 Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard  
391 Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as an  
392 Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician Scientist  
393 Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational  
394 Research Collaboration (BRC149/NS/MH). PF is supported by a Medical Research Council  
395 Senior Clinical Fellowship, an MRC/MND LEW Fellowship, the NIHR UCLH BRC and the Lady  
396 Edith Wolfson Fellowship scheme (MR/M008606/1 and MR/S006508/1).  
397 NSY was supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data  
398 Science Research Center, by a research grant from the Estate of Tully and Michele Plesser and  
399 by Maccabim Foundation. I.M. was supported by Teva Pharmaceutical Industries as part of the  
400 Israeli National Network of Excellence in Neuroscience (fellowship no. 117941).

401

402

403 **Authors' contribution**

404 I.M., P.F., J.D.R. and E.H. conceived research.

405 I.M., N.S.Y. and E.H. analyzed the data.

406 A.M. and J.D.R. established cohort, gained ethical approval and collected human samples for  
407 research.

408 Y.B., C.H. and I.S. assisted research.

409 I.M., N.S.Y., P.F., A.M., J.D.R. and E.H. wrote the manuscript, with comments and final  
410 approval by all other authors.

411 J.D.W. provided resources for research and input in research development.

412 A.M. and J.D.R. are corresponding authors for cohorts and clinical data. P.F. and E.H. are  
413 corresponding authors for all other facets of the work.

414 All authors read and approved the final manuscript.

415 **Declarations of interest**

416 None.



## 417 **References**

- 418 1. McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of  
419 frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's  
420 Disease. *Arch Neurol*. Nov 2001;58(11):1803-9. doi:10.1001/archneur.58.11.1803
- 421 2. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and  
422 pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry*.  
423 May 2011;82(5):476-86. doi:10.1136/jnnp.2010.212225
- 424 3. Convery R, Mead S, Rohrer JD. Review: Clinical, genetic and neuroimaging features of  
425 frontotemporal dementia. *Neuropathol Appl Neurobiol*. Feb 2019;45(1):6-18.  
426 doi:10.1111/nan.12535
- 427 4. Deleon J, Miller BL. Frontotemporal dementia. *Handb Clin Neurol*. 2018;148:409-430.  
428 doi:10.1016/B978-0-444-64076-5.00027-2
- 429 5. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC  
430 hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and  
431 ALS. *Neuron*. Oct 20 2011;72(2):245-56. doi:10.1016/j.neuron.2011.09.011
- 432 6. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72  
433 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*. Oct 20 2011;72(2):257-68.  
434 doi:10.1016/j.neuron.2011.09.010
- 435 7. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations  
436 in tau with the inherited dementia FTDP-17. *Nature*. Jun 18 1998;393(6686):702-5.  
437 doi:10.1038/31508
- 438 8. Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-  
439 complex subunit CHMP2B in frontotemporal dementia. *Nat Genet*. Aug 2005;37(8):806-8.  
440 doi:10.1038/ng1609
- 441 9. Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-  
442 negative frontotemporal dementia linked to chromosome 17. *Nature*. Aug 24  
443 2006;442(7105):916-9. doi:10.1038/nature05016
- 444 10. Borroni B, Bonvicini C, Alberici A, et al. Mutation within TARDBP leads to frontotemporal  
445 dementia without motor neuron disease. *Hum Mutat*. Nov 2009;30(11):E974-83.  
446 doi:10.1002/humu.21100
- 447 11. Pottier C, Bieniek KF, Finch N, et al. Whole-genome sequencing reveals important role  
448 for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron  
449 disease. *Acta Neuropathol*. Jul 2015;130(1):77-92. doi:10.1007/s00401-015-1436-x
- 450 12. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget  
451 disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat*  
452 *Genet*. Apr 2004;36(4):377-81. doi:10.1038/ng1332
- 453 13. Lippa CF, Zhukareva V, Kawarai T, et al. Frontotemporal dementia with novel tau  
454 pathology and a Glu342Val tau mutation. *Ann Neurol*. Dec 2000;48(6):850-8.
- 455 14. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal  
456 lobar degeneration and amyotrophic lateral sclerosis. *Science*. Oct 6 2006;314(5796):130-3.  
457 doi:10.1126/science.1134108
- 458 15. Snowden JS, Neary D, Mann DM. Frontotemporal dementia. *Br J Psychiatry*. Feb  
459 2002;180:140-3.
- 460 16. Olney NT, Spina S, Miller BL. Frontotemporal Dementia. *Neurol Clin*. May 2017;35(2):339-  
461 374. doi:10.1016/j.ncl.2017.01.008
- 462 17. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal  
463 spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral Scler*  
464 *Frontotemporal Degener*. May 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768

- 465 18. Teunissen CE, Elias N, Koel-Simmelink MJ, et al. Novel diagnostic cerebrospinal fluid  
466 biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics.  
467 *Alzheimers Dement (Amst)*. 2016;2:86-94. doi:10.1016/j.dadm.2015.12.004
- 468 19. Sheikh-Bahaei N, Sajjadi SA, Pierce AL. Current role for biomarkers in clinical diagnosis  
469 of Alzheimer disease and frontotemporal dementia. *Current treatment options in neurology*.  
470 2017;19(12):46.
- 471 20. Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC. Imaging and fluid biomarkers in  
472 frontotemporal dementia. *Nature Reviews Neurology*. 2017;13(7):406.
- 473 21. Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and  
474 phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology*. Apr 3  
475 2018;90(14):e1231-e1239. doi:10.1212/WNL.0000000000005261
- 476 22. Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-Based  
477 Biomarker for ALS and FTL. *Mol Neurobiol*. Oct 2018;55(10):7789-7801. doi:10.1007/s12035-  
478 018-0947-6
- 479 23. Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament  
480 light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic  
481 lateral sclerosis: A systematic review and meta-analysis. *Alzheimers Dement (Amst)*. Dec  
482 2019;11:730-743. doi:10.1016/j.dadm.2019.08.009
- 483 24. Delaby C, Alcolea D, Carmona-Iragui M, et al. Differential levels of Neurofilament Light  
484 protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. *Sci*  
485 *Rep*. Jun 8 2020;10(1):9161. doi:10.1038/s41598-020-66090-x
- 486 25. van der Ende EL, Xiao M, Xu D, et al. Neuronal pentraxin 2: a synapse-derived CSF  
487 biomarker in genetic frontotemporal dementia. *J Neurol Neurosurg Psychiatry*. Jun  
488 2020;91(6):612-621. doi:10.1136/jnnp-2019-322493
- 489 26. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic  
490 value of plasma neurofilament light. *Nat Commun*. Jun 7 2021;12(1):3400. doi:10.1038/s41467-  
491 021-23620-z
- 492 27. Katisko K, Cajanus A, Huber N, et al. GFAP as a biomarker in frontotemporal dementia  
493 and primary psychiatric disorders: diagnostic and prognostic performance. *J Neurol Neurosurg*  
494 *Psychiatry*. Dec 2021;92(12):1305-1312. doi:10.1136/jnnp-2021-326487
- 495 28. Verde F, Otto M, Silani V. Neurofilament Light Chain as Biomarker for Amyotrophic Lateral  
496 Sclerosis and Frontotemporal Dementia. *Front Neurosci*. 2021;15:679199.  
497 doi:10.3389/fnins.2021.679199
- 498 29. Wilson KM, Katona E, Galaria I, et al. Development of a sensitive trial-ready poly(GP) CSF  
499 biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral  
500 sclerosis. *J Neurol Neurosurg Psychiatry*. Jul 2022;93(7):761-771. doi:10.1136/jnnp-2021-  
501 328710
- 502 30. Katisko K, Cajanus A, Jaaskelainen O, et al. Serum neurofilament light chain is a  
503 discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric  
504 disorders. *J Neurol*. Jan 2020;267(1):162-167. doi:10.1007/s00415-019-09567-8
- 505 31. Hansson O, Santillo AF, Meeter LH, et al. CSF placental growth factor - a novel candidate  
506 biomarker of frontotemporal dementia. *Ann Clin Transl Neurol*. May 2019;6(5):863-872.  
507 doi:10.1002/acn3.763
- 508 32. Al Shweiki MR, Steinacker P, Oeckl P, et al. Neurofilament light chain as a blood  
509 biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia.  
510 *J Psychiatr Res*. Jun 2019;113:137-140. doi:10.1016/j.jpsychires.2019.03.019
- 511 33. Borroni B, Benussi A, Archetti S, et al. Csf p-tau181/tau ratio as biomarker for TDP  
512 pathology in frontotemporal dementia. *Amyotroph Lateral Scler Frontotemporal Degener*. Mar  
513 2015;16(1-2):86-91. doi:10.3109/21678421.2014.971812
- 514 34. Bourbouli M, Rentzos M, Bougea A, et al. Cerebrospinal Fluid TAR DNA-Binding Protein  
515 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and

- 516 Frontotemporal Dementia Spectrum Disorders. *Dement Geriatr Cogn Disord*. 2017;44(3-4):144-  
517 152. doi:10.1159/000478979
- 518 35. Hu WT, Watts K, Grossman M, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker  
519 for FTLTD-TDP. *Neurology*. Nov 26 2013;81(22):1945-52.  
520 doi:10.1212/01.wnl.0000436625.63650.27
- 521 36. Jiskoot LC, Panman JL, Meeter LH, et al. Longitudinal multimodal MRI as prognostic and  
522 diagnostic biomarker in presymptomatic familial frontotemporal dementia. *Brain*. Jan 1  
523 2019;142(1):193-208. doi:10.1093/brain/awy288
- 524 37. McCarthy J, Collins DL, Ducharme S. Morphometric MRI as a diagnostic biomarker of  
525 frontotemporal dementia: A systematic review to determine clinical applicability. *Neuroimage Clin*.  
526 2018;20:685-696. doi:10.1016/j.nicl.2018.08.028
- 527 38. Niikado M, Chrem-Mendez P, Itzcovich T, et al. Evaluation of Cerebrospinal Fluid  
528 Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. *J Gerontol A Biol Sci Med*  
529 *Sci*. Mar 14 2019;74(4):442-445. doi:10.1093/gerona/gly179
- 530 39. Benussi A, Karikari TK, Ashton N, et al. Diagnostic and prognostic value of serum NfL and  
531 p-Tau(181) in frontotemporal lobar degeneration. *J Neurol Neurosurg Psychiatry*. Sep  
532 2020;91(9):960-967. doi:10.1136/jnnp-2020-323487
- 533 40. Das S, Dewit N, Jacobs D, et al. A Novel Neurofilament Light Chain ELISA Validated in  
534 Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline,  
535 and the Evaluation of Candidate Proteins for Immunoassay Calibration. *Int J Mol Sci*. Jun 29  
536 2022;23(13)doi:10.3390/ijms23137221
- 537 41. Bellini S, Saraceno C, Benussi L, et al. Plasma Small Extracellular Vesicles with  
538 Complement Alterations in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration.  
539 *Cells*. Jan 30 2022;11(3)doi:10.3390/cells11030488
- 540 42. Chouliaras L, Thomas A, Malpetti M, et al. Differential levels of plasma biomarkers of  
541 neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and  
542 progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry*. Jun 2022;93(6):651-658.  
543 doi:10.1136/jnnp-2021-327788
- 544 43. Eratne D, Loi SM, Li QX, et al. Cerebrospinal fluid neurofilament light chain differentiates  
545 primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal  
546 disorders in clinical settings. *Alzheimers Dement*. Feb 1 2022;doi:10.1002/alz.12549
- 547 44. Krishnan G, Raitcheva D, Bartlett D, et al. Poly(GR) and poly(GA) in cerebrospinal fluid  
548 as potential biomarkers for C9ORF72-ALS/FTD. *Nat Commun*. May 19 2022;13(1):2799.  
549 doi:10.1038/s41467-022-30387-4
- 550 45. Oeckl P, Anderl-Straub S, Von Arnim CAF, et al. Serum GFAP differentiates Alzheimer's  
551 disease from frontotemporal dementia and predicts MCI-to-dementia conversion. *J Neurol*  
552 *Neurosurg Psychiatry*. Apr 27 2022;doi:10.1136/jnnp-2021-328547
- 553 46. Silva-Spinola A, Lima M, Leitao MJ, et al. Serum neurofilament light chain as a surrogate  
554 of cognitive decline in sporadic and familial frontotemporal dementia. *Eur J Neurol*. Jan  
555 2022;29(1):36-46. doi:10.1111/ene.15058
- 556 47. Thijssen EH, Verberk IMW, Kindermans J, et al. Differential diagnostic performance of a  
557 panel of plasma biomarkers for different types of dementia. *Alzheimers Dement (Amst)*.  
558 2022;14(1):e12285. doi:10.1002/dad2.12285
- 559 48. Meeter LH, Dopfer EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic  
560 frontotemporal dementia. *Ann Clin Transl Neurol*. Aug 2016;3(8):623-36. doi:10.1002/acn3.325
- 561 49. Coenen-Stass AML, Magen I, Brooks T, et al. Evaluation of methodologies for microRNA  
562 biomarker detection by next generation sequencing. *RNA Biol*. 2018;15(8):1133-1145.  
563 doi:10.1080/15476286.2018.1514236
- 564 50. van den Berg MMJ, Krauskopf J, Ramaekers JG, Kleinjans JCS, Prickaerts J, Briede JJ.  
565 Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders.  
566 *Prog Neurobiol*. Feb 2020;185:101732. doi:10.1016/j.pneurobio.2019.101732


- 567 51. Magen I, Aharoni S, Yacovzada NS, et al. Muscle microRNAs in the cerebrospinal fluid  
568 predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy  
569 patients. *Eur J Neurol*. Aug 2022;29(8):2420-2430. doi:10.1111/ene.15382
- 570 52. Magen I, Yacovzada NS, Yanowski E, et al. Circulating miR-181 is a prognostic biomarker  
571 for amyotrophic lateral sclerosis. *Nat Neurosci*. Nov 2021;24(11):1534-1541.  
572 doi:10.1038/s41593-021-00936-z
- 573 53. Denk J, Oberhauser F, Kornhuber J, et al. Specific serum and CSF microRNA profiles  
574 distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer  
575 patients and cognitively healthy controls. *PLoS One*. 2018;13(5):e0197329.  
576 doi:10.1371/journal.pone.0197329
- 577 54. Grasso M, Piscopo P, Talarico G, et al. Plasma microRNA profiling distinguishes patients  
578 with frontotemporal dementia from healthy subjects. *Neurobiol Aging*. Feb 5  
579 2019;doi:10.1016/j.neurobiolaging.2019.01.024
- 580 55. Piscopo P, Grasso M, Puopolo M, et al. Circulating miR-127-3p as a Potential Biomarker  
581 for Differential Diagnosis in Frontotemporal Dementia. *J Alzheimers Dis*. 2018;65(2):455-464.  
582 doi:10.3233/JAD-180364
- 583 56. Sheinerman KS, Toledo JB, Tsivinsky VG, et al. Circulating brain-enriched microRNAs as  
584 novel biomarkers for detection and differentiation of neurodegenerative diseases. *Alzheimers Res*  
585 *Ther*. Nov 9 2017;9(1):89. doi:10.1186/s13195-017-0316-0
- 586 57. Schneider R, McKeever P, Kim T, et al. Downregulation of exosomal miR-204-5p and  
587 miR-632 as a biomarker for FTD: a GENFI study. *J Neurol Neurosurg Psychiatry*. Aug  
588 2018;89(8):851-858. doi:10.1136/jnnp-2017-317492
- 589 58. Kmetzsch V, Anquetil V, Saracino D, et al. Plasma microRNA signature in presymptomatic  
590 and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic  
591 lateral sclerosis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2021;92(5):485-493.
- 592 59. Sproviero D, Gagliardi S, Zucca S, et al. Different miRNA Profiles in Plasma Derived Small  
593 and Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. *Int J Mol Sci*.  
594 Mar 8 2021;22(5)doi:10.3390/ijms22052737
- 595 60. Tan YJ, Wong BYX, Vaidyanathan R, et al. Altered Cerebrospinal Fluid Exosomal  
596 microRNA Levels in Young-Onset Alzheimer's Disease and Frontotemporal Dementia. *J*  
597 *Alzheimers Dis Rep*. 2021;5(1):805-813. doi:10.3233/ADR-210311
- 598 61. Muller M, Kuiperij HB, Versleijen AA, et al. Validation of microRNAs in Cerebrospinal Fluid  
599 as Biomarkers for Different Forms of Dementia in a Multicenter Study. *J Alzheimers Dis*. Apr 16  
600 2016;52(4):1321-33. doi:10.3233/JAD-160038
- 601 62. Pounders J, Hill EJ, Hooper D, et al. MicroRNA expression within neuronal-derived small  
602 extracellular vesicles in frontotemporal degeneration. *Medicine (Baltimore)*. Oct 7  
603 2022;101(40):e30854. doi:10.1097/MD.00000000000030854
- 604 63. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable  
605 prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann*  
606 *Intern Med*. Jan 6 2015;162(1):55-63. doi:10.7326/M14-0697
- 607 64. Kohen R, Barlev J, Hornung G, et al. UTAP: User-friendly Transcriptome Analysis  
608 Pipeline. *BMC bioinformatics*. 2019;24:154.
- 609 65. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using  
610 deep sequencing data. *Nucleic Acids Res*. Jan 2014;42(Database issue):D68-73.  
611 doi:10.1093/nar/gkt1181
- 612 66. Kho AT, Sharma S, Davis JS, et al. Circulating MicroRNAs: Association with Lung  
613 Function in Asthma. *PLoS One*. 2016;11(6):e0157998. doi:10.1371/journal.pone.0157998
- 614 67. Wander PL, Enquobahrie DA, Bammler TK, et al. Associations of plasma miRNAs with  
615 waist circumference and insulin resistance among women with polycystic ovary syndrome - Pilot  
616 study. *Mol Cell Endocrinol*. Aug 20 2022;554:111723. doi:10.1016/j.mce.2022.111723




- 617 68. Wang A, Kwee LC, Grass E, et al. Whole blood sequencing reveals circulating microRNA  
618 associations with high-risk traits in non-ST-segment elevation acute coronary syndrome.  
619 *Atherosclerosis*. Jun 2017;261:19-25. doi:10.1016/j.atherosclerosis.2017.03.041
- 620 69. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for  
621 RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
- 622 70. Elith J, Leathwick JR, Hastie T. A working guide to boosted regression trees. *J Anim Ecol*.  
623 Jul 2008;77(4):802-13. doi:10.1111/j.1365-2656.2008.01390.x
- 624 71. Witten IH, Frank E, Hall MA, Pal CJ. Ensemble Learning. In: Witten IH, Frank E, Hall MA,  
625 Pal CJ, eds. *Data Mining (Fourth Edition)*. Morgan Kaufmann; 2017:479-501:chap 12.
- 626 72. Lundberg SM, Erion G, Chen H, et al. From local explanations to global understanding  
627 with explainable AI for trees. *Nature Machine Intelligence*. 17 January 2020 2020;2:56-67.
- 628 73. Liu F, Li T, Hu P, Dai L. Upregulation of Serum miR-629 Predicts Poor Prognosis for Non-  
629 Small-Cell Lung Cancer. *Dis Markers*. 2021;2021:8819934. doi:10.1155/2021/8819934
- 630 74. Jingushi K, Ueda Y, Kitae K, et al. miR-629 Targets TRIM33 to Promote TGFbeta/Smad  
631 Signaling and Metastatic Phenotypes in ccRCC. *Mol Cancer Res*. Mar 2015;13(3):565-74.  
632 doi:10.1158/1541-7786.MCR-14-0300
- 633 75. Ludwig N, Leidinger P, Becker K, et al. Distribution of miRNA expression across human  
634 tissues. *Nucleic Acids Research*. 2016;44(8):3865-3877. doi:10.1093/nar/gkw116
- 635 76. Bu X, Li D, Wang F, Sun Q, Zhang Z. Protective Role of Astrocyte-Derived Exosomal  
636 microRNA-361 in Cerebral Ischemic-Reperfusion Injury by Regulating the AMPK/mTOR  
637 Signaling Pathway and Targeting CTSB. *Neuropsychiatr Dis Treat*. 2020;16:1863-1877.  
638 doi:10.2147/NDT.S260748
- 639 77. Hoerl AE, Kennard RW. Ridge Regression: Biased Estimation for Nonorthogonal  
640 Problems. *Technometrics*. 1970/02/01 1970;12(1):55-67. doi:10.1080/00401706.1970.10488634
- 641 78. Hoerl AE, Kennard RW. Ridge Regression: Applications to Nonorthogonal Problems.  
642 *Technometrics*. 1970/02/01 1970;12(1):69-82. doi:10.1080/00401706.1970.10488635
- 643 79. Chang WS, Wang YH, Zhu XT, Wu CJ. Genome-Wide Profiling of miRNA and mRNA  
644 Expression in Alzheimer's Disease. *Med Sci Monit*. Jun 4 2017;23:2721-2731.  
645 doi:10.12659/msm.905064
- 646 80. He B, Chen W, Zeng J, Tong W, Zheng P. MicroRNA-326 decreases tau phosphorylation  
647 and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in  
648 Alzheimer's disease. *J Cell Physiol*. Jan 2020;235(1):480-493. doi:10.1002/jcp.28988
- 649 81. Ludwig N, Fehlmann T, Kern F, et al. Machine Learning to Detect Alzheimer's Disease  
650 from Circulating Non-coding RNAs. *Genomics Proteomics Bioinformatics*. Aug 2019;17(4):430-  
651 440. doi:10.1016/j.gpb.2019.09.004
- 652 82. Allach El Khattabi L, Heide S, Caberg J-H, et al. 16p13.11 microduplication in 45 new  
653 patients: refined clinical significance and genotype-phenotype correlations. *Journal of Medical*  
654 *Genetics*. 2020;57(5):301-307. doi:10.1136/jmedgenet-2018-105389
- 655 83. Goncalves TF, Piergiorgio RM, Dos Santos JM, Gusmao J, Pimentel MMG, Santos-  
656 Reboucas CB. Network Profiling of Brain-Expressed X-Chromosomal MicroRNA Genes  
657 Implicates Shared Key MicroRNAs in Intellectual Disability. *J Mol Neurosci*. Feb 2019;67(2):295-  
658 304. doi:10.1007/s12031-018-1235-7
- 659 84. Wingo TS, Yang J, Fan W, et al. Brain microRNAs associated with late-life depressive  
660 symptoms are also associated with cognitive trajectory and dementia. *NPJ Genom Med*.  
661 2020;5:6. doi:10.1038/s41525-019-0113-8
- 662 85. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's  
663 disease brain and CSF yields putative biomarkers and insights into disease pathways. *J*  
664 *Alzheimers Dis*. May 2008;14(1):27-41. doi:10.3233/jad-2008-14103
- 665 86. Rawat P, Sehar U, Bisht J, Selman A, Culbertson J, Reddy PH. Phosphorylated Tau in  
666 Alzheimer's Disease and Other Tauopathies. *Int J Mol Sci*. Oct 25  
667 2022;23(21)doi:10.3390/ijms232112841

- 668 87. Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM. MicroRNAs in Alzheimer's  
669 disease: differential expression in hippocampus and cell-free cerebrospinal fluid. *Neurobiol Aging*.  
670 Jan 2014;35(1):152-8. doi:10.1016/j.neurobiolaging.2013.07.005
- 671 88. Nelson PT, Wang WX. MiR-107 is reduced in Alzheimer's disease brain neocortex:  
672 validation study. *J Alzheimers Dis*. 2010;21(1):75-9. doi:10.3233/JAD-2010-091603
- 673 89. Prendecki M, Florczak-Wyspianska J, Kowalska M, et al. APOE genetic variants and  
674 apoE, miR-107 and miR-650 levels in Alzheimer's disease. *Folia Neuropathol*. 2019;57(2):106-  
675 116. doi:10.5114/fn.2019.84828
- 676 90. Wang J, Chen C, Zhang Y. An investigation of microRNA-103 and microRNA-107 as  
677 potential blood-based biomarkers for disease risk and progression of Alzheimer's disease. *J Clin*  
678 *Lab Anal*. Jan 2020;34(1):e23006. doi:10.1002/jcla.23006
- 679 91. Yilmaz SG, Erdal ME, Ozge AA, Sungur MA. Can Peripheral MicroRNA Expression Data  
680 Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease? *OMICS*. Aug  
681 2016;20(8):456-61. doi:10.1089/omi.2016.0099
- 682 92. Wang WX, Rajeev BW, Stromberg AJ, et al. The expression of microRNA miR-107  
683 decreases early in Alzheimer's disease and may accelerate disease progression through  
684 regulation of beta-site amyloid precursor protein-cleaving enzyme 1. *J Neurosci*. Jan 30  
685 2008;28(5):1213-23. doi:10.1523/JNEUROSCI.5065-07.2008
- 686 93. Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L. Altered expression of miR-17-  
687 5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. *Eur J Immunol*. Mar  
688 2010;40(3):888-98. doi:10.1002/eji.200940032
- 689 94. Yang D, Wang WZ, Zhang XM, et al. MicroRNA expression aberration in Chinese patients  
690 with relapsing remitting multiple sclerosis. *J Mol Neurosci*. Jan 2014;52(1):131-7.  
691 doi:10.1007/s12031-013-0138-x
- 692 95. Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M. miR-326 and miR-  
693 26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-  
694 remitting multiple sclerosis. *Gene*. Jul 10 2014;544(2):128-33. doi:10.1016/j.gene.2014.04.069
- 695 96. Niwald M, Migdalska-Sek M, Brzezianska-Lasota E, Miller E. Evaluation of Selected  
696 MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to  
697 Cognition, Depression, and Disability. *J Mol Neurosci*. Dec 2017;63(3-4):275-282.  
698 doi:10.1007/s12031-017-0977-y
- 699 97. Regev K, Healy BC, Paul A, et al. Identification of MS-specific serum miRNAs in an  
700 international multicenter study. *Neurol Neuroimmunol Neuroinflamm*. Sep 2018;5(5):e491.  
701 doi:10.1212/NXI.0000000000000491
- 702 98. Sharaf-Eldin WE, Kishk NA, Gad YZ, et al. Extracellular miR-145, miR-223 and miR-326  
703 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory  
704 diseases. *J Neurol Sci*. Dec 15 2017;383:188-198. doi:10.1016/j.jns.2017.11.014
- 705 99. Baulina N, Kulakova O, Kiselev I, et al. Immune-related miRNA expression patterns in  
706 peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission. *J*  
707 *Neuroimmunol*. Apr 15 2018;317:67-76. doi:10.1016/j.jneuroim.2018.01.005
- 708 100. Dolati S, Aghebati-Maleki L, Ahmadi M, et al. Nanocurcumin restores aberrant miRNA  
709 expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. *J Cell*  
710 *Physiol*. Jul 2018;233(7):5222-5230. doi:10.1002/jcp.26301
- 711 101. Regev K, Healy BC, Khalid F, et al. Association Between Serum MicroRNAs and Magnetic  
712 Resonance Imaging Measures of Multiple Sclerosis Severity. *JAMA Neurol*. Mar 1  
713 2017;74(3):275-285. doi:10.1001/jamaneurol.2016.5197

714 Main figures and tables




715  
716 **Figure 1. miRNA signature associated with FTD.** MA plot of differential miRNA expression in plasma of  
717 patients with FTD vs non-neurodegenerative healthy controls in the **(A)** total cohort of FTD patients and  
718 controls (N=168 and N=125, respectively). **(B)** C9ORF72 mutations carriers only (N=18) vs healthy controls  
719 (N=125). **(C)** Female patients with FTD and healthy female controls (N=58 and N=85, respectively) **(D)**  
720 male patients with FTD and healthy male controls (N=110 and N=40, respectively). Log 2 transformed fold  
721 change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs (adjusted  
722  $p < 0.05$ , Wald test). Black: miRNAs showing insignificant change.




723  
 724 **Figure 2: Diagnosis of FTD by a distinctive cell free miRNA signature.** (A) Mean accuracy under 3-  
 725 fold cross validation (AUC ROC, y-axis) as a function of the number of plasma miRNAs used in the FTD  
 726 prediction model. Increasing numbers of miRNA features (x-axis) successively selected in the recursive  
 727 feature elimination process reveals a saturation at 13 miRNA features (red line). Final model included 15  
 728 features (including age and sex as covariates). (B) ROC curves in the training set: true positive rate (y-axis)  
 729 vs. false positive rate (x-axis). Mean values and variance of data from 219 samples with 3-fold cross  
 730 validation. Mean AUC  $0.94 \pm 0.02$ . 95% CI is 0.92-0.96. (C) Performance and generalizability on replication  
 731 held-out data revealed by an ROC curve with AUC of 0.88. (D) Reliability diagram, plotting truly observed  
 732 fraction of cases (upper plot, y-axis) vs. predicted probability by the prediction model (upper plot, x-axis), in  
 733 five probability bins, reveals a sufficiently calibrated model on the held-out set. Lower plot shows the number  
 734 of individuals at each of the five predicted probability bins. (E) Confusion matrix showing the prediction  
 735 errors on held out dataset. At a probability threshold of 0.6, we observed 0.92 Negative predictive value  
 736 (NPV), 0.81 Positive Predictive Value (PPV/precision), 0.91 recall (sensitivity) and 0.83 specificity. In  
 737 addition, a 0.17 False Positive Rate is obtained over 0.08 False Omission Rate and 0.19 false discovery  
 738 rate. (F) AUC ROC of a model trained with only a subset of top 15 most predictive features, reveals a  
 739 stable performance with the selected final features.






740  
741 **Figure 3: The contribution of individual miRNAs to the predictor of FTD diagnosis. (A)** Mean absolute  
742 SHapley Additive exPlanations (SHAP) values break down the impact of specific miRNAs on FTD disease  
743 non-linear predictor output in the held-out cohort. **(B)** Illustration of the relationship between the miRNA  
744 levels (low – blue to high – red), SHAP values and the impact on the prediction in the held-out cohort.  
745 Positive or negative SHAP value lead the model to a more likely FTD or healthy control predictions,  
746 respectively.



747  
748 **Figure 4. Distribution of the top 13 miRNA predictors in patients with FTD and controls.** Box plots  
749 with complement scatter plots of the 13 miRNA features predicting FTD, depicting expression values of all  
750 cohort along with distribution of each miRNA. Blue dots represent the levels of a given miRNA measured  
751 in healthy control participants. Red dots represent the levels of a given miRNA measured in patients with  
752 FTD. Box – two central data quartiles, with a line at the median (Q2). Whiskers extend to show the rest of  
753 the distribution, except for points that are determined to be outliers using a method that is a function of the  
754 inter-quartile range.



755  
756 **Figure 5. AUC values for different miRNA classifiers for discriminating FTD vs controls in the held-**  
757 **out data.** The classifiers were either the 13 selected in the FTD model in our data, a combination of miR-  
758 34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p [from ], or a combination of miR-335/let-7e, miR-99b/let-  
759 7e and miR-9-3p/miR-181a [from ];

	Control	FTD
Number of subjects (% males)	125 (32%)	168 (65.5%)
UCL controls	48 (45.8%)	
Queen Mary Hospital controls	77 (23.4%)	
Age at enrolment	59.5±10.2 yr.	65.8±8.1 yr.
UCL controls	65.6±7.3 yr.	
Queen Mary Hospital controls	55.7±10.0 yr	
Age of onset (1 <sup>st</sup> reported symptoms)		60.3±8.3 yr.
Disease duration at enrolment		5.5±3.4 yr.
FTD clinical subtype (bvFTD/PNFA/SD/FTD-ALS/others)		81/40/28/5/14
FTD Mutation carriers (C9ORF72/MAPT/GRN/TBK1)		18/13/13/2
Likely FTD pathology (TDP-43/Tau)		63/18


760 **Table 1. Summary of demographic and clinical characteristics of participants suffering from FTD**  
761 **and control samples.** bvFTD: behavioural FTD; PNFA: progressive nonfluent aphasia; SD: semantic  
762 dementia. Mean±SD.

<b>Predictor</b>	<b>Single Feature AUC</b>
miR-423-5p	0.69
miR-125b-5p	0.67
miR-26a-5p	0.66
sex	0.66
miR-326	0.65
miR-185-5p	0.64
age	0.64
miR-629-5p	0.63
miR-484	0.62
let-7d-3p	0.62
miR-107	0.62
let-7c-5p	0.61
miR-361-5p	0.59
miR-379-5p	0.56
miR-378a-5p	0.54


763 **Table 2. Predictive power of selected miRNA features, when used as a single predictor for FTD on**  
764 **held-out data.** Among the most predictive features are miRNAs expressed in the brain, such as miR-26a-  
765 5p, miR-125b-5p and let-7c-5p.

766 **Supplementary figure and tables**


t-SNE analysis of all control subjects presenting a desperation between the groups



767 **Supplementary Figure 1. t-SNE analysis of control subjects from Queen Mary Hospital (blue) and**  
768 **from UCL (red).** Similarity of the two control groups suggests they could have been taken from a single  
769 distribution which is justified further by an associated Kullback–Leibler divergence value of 0.293, a  
770 measure of the difference between two probability distributions.




771  
772 **Supplementary Figure 2. miRNA signature associated with FTD patients with predicted pathology.**  
773 MA plot of differential miRNA expression in plasma of patients with predicted TDP pathology (**A; N=63**) or  
774 Tau pathology (**B; N=19**) vs non-neurodegenerative healthy controls (N=125). Log 2 transformed fold  
775 change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs (adjusted  
776  $p < 0.05$ , Wald test). Black: miRNAs showing insignificant change.




777  
 778 **Supplementary Figure 3. Diagnosis of FTD by age, sex and 95 differentially-expressed miRNA in a**  
 779 **logistic regression model. (A)** ROC curves in the training set: true positive rate (y-axis) vs. false positive  
 780 rate (x-axis). Mean values and variance of data from 219 samples with 3-fold cross validation. Mean AUC  
 781  $0.91 \pm 0.05$ . 95% CI is 0.86-0.96. **(B)** Performance and generalizability on held-out data revealed by a ROC  
 782 curve with AUC of 0.9. **(C)** Reliability diagram, plotting truly observed fraction of cases (upper plot, y-axis)  
 783 vs. predicted probability by the prediction model (upper plot, x-axis), in five probability bins, reveals a  
 784 sufficiently calibrated model on the held-out set. Lower plot shows the number of individuals at each of the  
 785 five predicted probability bins. **(D)** Confusion matrix showing the prediction errors on held out dataset. At a  
 786 probability threshold of 0.6, we observed 0.8 Negative predictive value (NPV), 0.83 Positive Predictive  
 787 Value (PPV/precision), 0.73 recall (sensitivity) and 0.88 specificity. In addition, 0.12 False Positive Rate is  
 788 obtained, over 0.2 False Omission Rate and 0.17 false discovery rate.





789  
 790 **Supplementary Figure 4. Levels of 13 miRNA predictors in different FTD subtypes.** miRNA levels for  
 791 PNFA (progressive nonfluent aphasia), SD (semantic dementia), behavioral FTD (bvFTD) and the following  
 792 subtypes: primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy and FTD  
 793 with motor neuron disease, commonly referred to as “Other”. Box plot with two central data quartiles, with  
 794 a line at the median (Q2). Whiskers extend to show the rest of the distribution, except for points that are  
 795 determined to be outliers using a method that is a function of the inter-quartile range. Data were analyzed  
 796 by one-way ANOVA. Post-hoc Bonferroni was conducted only for miR-107 (C) and miR-26a-5p (F) which  
 797 showed significant differences in ANOVA. Significant pairwise differences in miR-107 levels were found  
 798 between other FTD subtypes and both bvFTD (p=0.01) and SD (p=0.02). Significant pairwise differences  
 799 in miR-26a were found between other FTD subtypes and both bvFTD (p=0.04) and PNFA (p=0.02).



800  
 801 **Supplementary Figure 5. Levels of 13 miRNA predictors in mutations carriers.** miRNA levels for FTD  
 802 patients without known FTD mutations, or with mutations in C9ORF72, Progranulin (GRN), Tau (MAPT)  
 803 and TBK1. Box plot with two central data quartiles, with a line at the median (Q2). Whiskers extend to show  
 804 the rest of the distribution, except for points that are determined to be outliers using a method that is a  
 805 function of the inter-quartile range. Data were analyzed by one-way ANOVA.

<b>Group Name</b>	<b>Before Exclusion</b>				<b>After Exclusion</b>		
	<b>Age [95% CI]</b>	<b>Sex</b>	<b>Mean Age</b>	<b>Group Size</b>	<b>Age [95% CI]</b>	<b>Mean Age</b>	<b>Group Size</b>
<b>controls total (n=158)</b>	53.8±14.5, 95% CI [51.5, 56.1]	<b>F</b>	54.0	103	59.5±10.2, 95% CI [57.7, 61.3]	58.4	85
		<b>M</b>	53.4	55		61.7	40
<b>UCL controls (n=56)</b>	61.0± 13.3, 95% CI [57.4, 64.5]	<b>F</b>	61.1	30	65.55± 7.3, 95% CI [63.4, 67.7]	65.6	26
		<b>M</b>	60.8	26		65.5	22
<b>Queen Mary Hospital controls (n=102)</b>	49.9±13.7, 95% CI [47.2, 52.6]	<b>F</b>	51.1	73	55.7±10.0, 95% CI [53.4, 58.0]	55.3	59
		<b>M</b>	46.8	29		57.0	18
<b>FTD cases (n=169)</b>	65.6± 8.3, 95% CI [64.4, 67.0]	<b>F</b>	66.8	59	65.8±8.1, 95% CI [64.6, 67.0]	67.4	58
		<b>M</b>	65.0	110		65.0	110

806 **Supplementary Table 1.** Age and sex characteristics of the cohort and exclusion by age of 34 individuals  
807 that were below 40 years of age during blood collection.